What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?

30Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In vitro and in vivo experimental data have pointed to new immunopathogenic mechanisms in primary Sjögren's syndrome (pSS). The availability of targeted treatment modalities has opened new ways to selectively target these mechanistic pathways in vivo. This has taught us that the role of proinflammatory cytokines, in particular TNFα, is not crucial in the immunopathogenesis of pSS. B cells appear to play a major role, as depletion of B cells leads to restoration of salivary flow and is efficacious for treatment of extraglandular manifestations and mucosa-associated lymphoid tissue lymphoma. B cells also orchestrate T-cell infiltration and ductal epithelial dearrangement in the salivary glands. Gene profiling of salivary gland tissue in relation to B-cell depletion confirms that the axis of IFNα, B-cell activating factor, B-cell activation, proliferation and survival constitutes a major pathogenic route in pSS. © 2011 BioMed Central Ltd.

Cite

CITATION STYLE

APA

Kallenberg, C. G. M., Vissink, A., Kroese, F. G. M., Abdulahad, W. H., & Bootsma, H. (2011, February 28). What have we learned from clinical trials in primary Sjögren’s syndrome about pathogenesis? Arthritis Research and Therapy. https://doi.org/10.1186/ar3234

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free